Kolexia
Mateescu Cristian Oncologie médicale
Mateescu Cristian
Oncologie médicale
Yso 78
Trappes, France
41 Activités
429 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs neuroendocrines Tumeurs neuroectodermiques primitives Ascites Tumeurs de la prostate Tumeurs colorectales {{person.topmesh7.name}} {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Collaborateurs

Voir plus
Soltys Barbara
Soltys Barbara
Centre Hospitalier de Rambouillet, Rambouillet, France
Neji Mohamed
Neji Mohamed
Hopital Prive Franciscaines, Versailles, France
Cappele Olivier
Cappele Olivier
Hôpital de Houdan, Houdan, France
Kamioner Didier
Kamioner Didier
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
MSD
16 collaboration(s)
Dernière en 2023
Ipsen
12 collaboration(s)
Dernière en 2023
Leo Pharma
7 collaboration(s)
Dernière en 2023
B3TSI
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Anti-PD1 inhibitors: Assessment of proper use, efficacy and economic impact in daily practice
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
Efficacy of additional chemotherapy following failure of currently approved therapies in patients with castration-resistant prostate cancer.
2017 Genitourinary Cancers Symposium   29 mars 2017
Assessment of tumor-infiltrating lymphocytes and immune-checkpoints expression in metastatic colorectal cancer patients.
2016 ASCO Annual Meeting I   20 mai 2016
Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.
2014 ASCO Annual Meeting I   20 mai 2014
Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   01 novembre 2012
Response Evaluation Using Recist and Choi Criteria in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (PNET) Treated with Sunitinib or Everolimus
Abstract Book of the 37th ESMO Congress Vienna, Austria, 28 September - 2 October 2012   01 septembre 2012
Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus.
2012 ASCO Annual Meeting I   20 mai 2012
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}